Yıl: 2020 Cilt: 32 Sayı: 2 Sayfa Aralığı: 59 - 67 Metin Dili: İngilizce DOI: 10.5336/cardiosci.2020-75417 İndeks Tarihi: 02-12-2020

Single-Center Retrospective Evaluation of Clinical Features and Life Expectancy in Mid-Range/Reduced Left Ventricular Ejection Fraction Heart Failure Patients Who Died During Hospitalization

Öz:
Objective: Today, despite medical developments the frequency of heart failure is increasing. The current guidelines have categorized patients with heart failure (HF) by their phenotypes to betterexplain them. In our study, we aimed to compare the basic clinical features, drug treatment and the life expectancy in HF phenotypes who diedduring hospitalization. Material and Methods: 100 consecutive patientswho admitted with HF between 2011 and 2018 and died of cardiac causeduring last hospitalization were evaluated. Patients with left ventricleejection fraction (LVEF) 41-49% and N-terminal pro-B type natriureticpeptide (NT-proBNP) level >125 pg/mL were classified in the study asHFmrEF. Patients with EF% ≤40 NT-proBNP level >125 pg/mL wereclassified in the study as HFrEF. There were 50 patients from each HFgroup. Patients' demographic features, major laboratory parameters, drugtreatments and life expectancy were evaluated in retrospective analysis.SPSS version 17.0 program was used for statistical analysis. p<0.05 wasconsidered statistically significant. Results: The LVEF values of HFrEFand HFmrEF patients were 30% (15-38) and 45% (40-49), respectively.There was no significant difference between groups in drug treatment.The life expectancy values of the groups were 15 (1-61) months in theHFmrEF group and 11 (1-49) months in the HFrEF group (p=0.043).Conclusion: In our study, it was concluded that the demographic characteristics of HFrEF and HFmrEF patients were different. The life expectancy in HFmrEF group was longer than in HFrEF group.
Anahtar Kelime:

Hastanede Yatış Sırasında Ölen Sınırda/Düşük Ejeksiyon Fraksiyonlu Kalp Yetersizliği Hastalarında Klinik Özelliklerin ve Yaşam Süresinin Tek Merkezli Retrospektif Değerlendirilmesi

Öz:
Amaç: Günümüzde, medikal gelişmelere rağmen kalp yetersizliği (KY) sıklığı artmaktadır. Mevcut kılavuzlar kalp yetersizliği hastalarını daha iyi açıklamak için fenotiplerine göre sınıflandırmıştır. Biz çalışmamızda, hastanede ölen KY fenotiplerinin temel klinik özelliklerini, ilaç tedavilerini ve yaşam sürelerini kıyaslamayı hedefledik. Gereç ve Yöntemler: 2011-2018 yılları arasında kalp yetersizliği ile başvuran ve son hastaneye yatışı sırasında kardiyak nedenden ölen 100 ardışık hasta değerlendirildi. Çalışmada EF% 41-49 ve N-terminal proB tipi natriüretik peptit (NT-proBNP) düzeyi >125 pg/mL olan hastalar SEF-KY olarak sınıflandırıldı. Çalışmada EF%≤40 ve NT-proBNP düzeyi >125 pg/mL olan hastalar DEF-KY olarak sınıflandırıldı. Her iki KY grubunda 50 hasta vardı. Retrospektif analizimizde hastaların demografik özellikleri, başlıca laboratuvar parametreleri, ilaç tedavileri ve tahmini yaşam süreleri değerlendirildi. İstatistiksel incelemede SPSS versiyon 17.0 programı kullanıldı. p<0,05 istatiksel olarak anlamlı kabul edildi. Bulgular: DEF-KY ve SEF-KY hastalarının EF değerleri sırasıyla %30 (15-38) ve %45 (40-49) idi. İlaç tedavilerinde gruplar arasında anlamlı bir fark yoktu. Grupların yaşam sürelerinin değerleri SEF-KY grubunda 15 (1-61) ay ve DEF-KY grubunda 11 (1-49) ay olarak saptandı (p=0.043). Sonuç: Çalışmamızda DEF-KY ve SEF-KY hastalarının demografik özelliklerinin farklı olduğu sonucuna varıldı. SEF-KY grubundaki yaşam süresi DEF-KY grubuna göre daha uzundu.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53(15):e1-90.
  • 2. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993;22(4 Suppl A):6A-13A. [Crossref]
  • 3. Cubbon RM, Gale CP, Kearney LC, Schechter CB, Brooksby WP, Nolan J, et al. Changing characteristics and mode of death associated with chronic heart failure caused by left ventricular systolic dysfunction: a study across therapeutic eras. Circ Heart Fail. 2011;4(4): 396-403. [Crossref] [PubMed]
  • 4. Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation. 2003;108(8):977-82. [Crossref] [PubMed]
  • 5. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341(10):709-17. [Crossref] [PubMed]
  • 6. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey Jr DE, Drazner MH, et al; American College of Cardiology Foundation, American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147-239.
  • 7. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200.
  • 8. Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC heart failure long-term registry. Eur J Heart Fail. 2017;19(12):1574- 85. [Crossref] [PubMed]
  • 9. Rickenbacher P, Kaufmann BA, Maeder MT, Bernheim A, Goetschalckx K, Pfister O, et al; TIME-CHF Investigators. Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the trial of intensified versus standard medical therapy in elderly patients with Congestive Heart Failure (TIME-CHF). Eur J Heart Fail. 2017;19(12): 1586-96. [Crossref] [PubMed]
  • 10. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J Fail. 2016;18(8):891-975.
  • 11. Lam CSP, Solomon SD. Fussing over the middle child: heart failure with mid-range ejection fraction. Circulation. 2017;135(14):1279-80. [Crossref] [PubMed]
  • 12. Rastogi A, Novak E, Platts AE, Mann DL. Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction. Eur J Heart Fail. 2017;19(12):1597-605. [Crossref] [PubMed] [PMC]
  • 13. MB Yılmaz, Çelik A, Çavuşoğlu Y, Bekar L, Onrat E, Eren M, et al. [Snapshot evaluation of heart failure in Turkey: baseline characteristics of SELFIE-TR]. Turk Kardiyol Dern Ars. 2019;47(3):198-206.
  • 14. McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD. Confirmation of a heart failure epidemic: findings from the resource utilization among congestive heart failure (REACH) study. J Am Coll Cardiol. 2002;39(1):60-9. [Crossref]
  • 15. Değertekin M, Erol C, Ergene O, Tokgözoğlu L, Aksoy M, Erol MK, et al. [Heart failure prevalence and predictors in Turkey: HAPPY study]. Turk Kardiyol Dern Ars. 2012;40(4): 298-308. [Crossref] [PubMed]
  • 16. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93(9):1137-46. [Crossref] [PubMed] [PMC]
  • 17. Kapoor JR, Kapoor R, Ju C, Heidenreich PA, Eapen ZJ, Hernandez AF, et al. Precipitating clinical factors, heart failure characterization, and outcomes in patients hospitalized with heart failure with reduced, borderline, and preserved ejection fraction. JACC Heart Fail. 2016;4(6):464-72. [Crossref] [PubMed]
  • 18. Coles AH, Tisminetzky M, Yarzebski J, Lessard D, Gore JM, Darling CE, et al. Magnitude of and prognostic factors associated with 1-year mortality after hospital discharge for acute decompensated heart failure based on ejection fraction findings. J Am Heart Assoc. 2015;4(12):e002303. [Crossref] [PubMed] [PMC]
  • 19. Cheng RK, Cox M, Neely ML, Heidenreich PA, Bhatt DL, Eapen ZJ, et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the medicare population. Am Heart J. 2014; 168(5):721-30. [Crossref] [PubMed]
  • 20. Dunlay SM, Roger VL, Weston SA, Jiang R, Redfield MM. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail. 2012;5(6):720-6. [Crossref] [PubMed] [PMC]
  • 21. Nadruz Jr W, West E, Santos M, Skali H, Groarke JD, Forman DE, et al. Heart failure and midrange ejection fraction: implications of recovered ejection fraction for exercise tolerance and outcomes. Circ Heart Fail. 2016;9(4):e002826. [Crossref] [PubMed] [PMC]
  • 22. Ibrahim NE, Song Y, Cannon CP, Doros G, Russo P, Ponirakis A, et al. Heart failure with mid-range ejection fraction: characterization of patients from the PINNACLE Registry®. ESC Heart Fail. 2019;6(4):784-92. [Crossref] [PubMed] [PMC]
  • 23. Tsuji K, Sakata Y, Nochioka K, Miura M, Yamauchi T, Onose T, et al. Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 study. Eur J Heart Fail. 2017;19(10):1258-69. [Crossref] [PubMed]
  • 24. Bloomfield GS, Barasa FA, Doll JA, Velazquez EJ. Heart failure in sub-Saharan Africa. Curr Cardiol Rev. 2013;9(2):157-73. [Crossref] [PubMed] [PMC]
  • 25. Lauritsen J, Gustafsson F, Abdulla J. Characteristics and long-term prognosis of patients with heart failure and mid-range ejection fraction compared with reduced and preserved ejection fraction: a systematic review and meta-analysis. ESC Heart Fail. 2018;5(4):685- 94. [Crossref] [PubMed] [PMC]
  • 26. Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. 2012;126(1):65-75. [Crossref] [PubMed]
  • 27. Koh AS, Tay WT, Teng THK, Vedin O, Benson L, Dahlstrom U, et al. A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur J Heart Fail. 2017;19(12):1624-34. [Crossref] [PubMed
  • 28. Löfman I, Szummer K, Dahlström U, Jernberg T, Lund LH. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction. Eur J Heart Fail. 2017;19(12):1606-14. [Crossref] [PubMed]
  • 29. Webb J, Draper J, Fovargue L, Sieniewicz B, Gould J, Claridge S, et al. Is heart failure with mid range ejection fraction (HFmrEF) a distinct clinical entity or an overlap group? Int J Cardiol Heart Vasc. 2018;21:1-6. [Crossref] [PubMed] [PMC]
  • 30. Nielsen OW, Valeur N, Sajadieh A, FabriciusBjerre A, Carlsen CM, Kober L. Echocardiographic subtypes of heart failure in consecutive hospitalised patients with dyspnoea. Open Heart. 2019;6(1):e000928. [Crossref] [PubMed] [PMC]
  • 31. Chen X, Xin Y, Hu W, Zhao Y, Zhang Z, Zhou Y. Quality of life and outcomes in heart failure patients with ejection fractions in different ranges. PLoS One. 2019;14(6):e0218983. [Crossref] [PubMed] [PMC]
  • 32. Solomon SD, Anavekar N, Skali H, Mcmurray JJV, Swedberg K, Yusuf S, et al; Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation. 2005;112(24):3728-44. [Crossref] [PubMed]
  • 33. Bonsu KO, Owusu IK, Buabeng KO, Reidpath DD, Kadirvelu A. Clinical characteristics and prognosis of patients admitted for heart failure: a 5-year retrospective study of African patients. Int J Cardiol. 2017;238:128-35. [Crossref] [PubMed]
  • 34. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med. 2008;168(8):847-54. [Crossref] [PubMed]
  • 35. Lyu S, Yu L, Tan H, Liu S, Liu X, Guo X, et al. Clinical characteristics and prognosis of heart failure with mid-range ejection fraction: insights from a multi-centre registry study in China. BMC Cardiovasc Disord. 2019;19(1):209. [Crossref] [PubMed] [PMC]
APA DİNDAŞ F, Turgut O, YILMAZ M (2020). Single-Center Retrospective Evaluation of Clinical Features and Life Expectancy in Mid-Range/Reduced Left Ventricular Ejection Fraction Heart Failure Patients Who Died During Hospitalization. , 59 - 67. 10.5336/cardiosci.2020-75417
Chicago DİNDAŞ FERHAT,Turgut Okan,YILMAZ MEHMET BIRHAN Single-Center Retrospective Evaluation of Clinical Features and Life Expectancy in Mid-Range/Reduced Left Ventricular Ejection Fraction Heart Failure Patients Who Died During Hospitalization. (2020): 59 - 67. 10.5336/cardiosci.2020-75417
MLA DİNDAŞ FERHAT,Turgut Okan,YILMAZ MEHMET BIRHAN Single-Center Retrospective Evaluation of Clinical Features and Life Expectancy in Mid-Range/Reduced Left Ventricular Ejection Fraction Heart Failure Patients Who Died During Hospitalization. , 2020, ss.59 - 67. 10.5336/cardiosci.2020-75417
AMA DİNDAŞ F,Turgut O,YILMAZ M Single-Center Retrospective Evaluation of Clinical Features and Life Expectancy in Mid-Range/Reduced Left Ventricular Ejection Fraction Heart Failure Patients Who Died During Hospitalization. . 2020; 59 - 67. 10.5336/cardiosci.2020-75417
Vancouver DİNDAŞ F,Turgut O,YILMAZ M Single-Center Retrospective Evaluation of Clinical Features and Life Expectancy in Mid-Range/Reduced Left Ventricular Ejection Fraction Heart Failure Patients Who Died During Hospitalization. . 2020; 59 - 67. 10.5336/cardiosci.2020-75417
IEEE DİNDAŞ F,Turgut O,YILMAZ M "Single-Center Retrospective Evaluation of Clinical Features and Life Expectancy in Mid-Range/Reduced Left Ventricular Ejection Fraction Heart Failure Patients Who Died During Hospitalization." , ss.59 - 67, 2020. 10.5336/cardiosci.2020-75417
ISNAD DİNDAŞ, FERHAT vd. "Single-Center Retrospective Evaluation of Clinical Features and Life Expectancy in Mid-Range/Reduced Left Ventricular Ejection Fraction Heart Failure Patients Who Died During Hospitalization". (2020), 59-67. https://doi.org/10.5336/cardiosci.2020-75417
APA DİNDAŞ F, Turgut O, YILMAZ M (2020). Single-Center Retrospective Evaluation of Clinical Features and Life Expectancy in Mid-Range/Reduced Left Ventricular Ejection Fraction Heart Failure Patients Who Died During Hospitalization. Türkiye Klinikleri Cardiovascular Sciences, 32(2), 59 - 67. 10.5336/cardiosci.2020-75417
Chicago DİNDAŞ FERHAT,Turgut Okan,YILMAZ MEHMET BIRHAN Single-Center Retrospective Evaluation of Clinical Features and Life Expectancy in Mid-Range/Reduced Left Ventricular Ejection Fraction Heart Failure Patients Who Died During Hospitalization. Türkiye Klinikleri Cardiovascular Sciences 32, no.2 (2020): 59 - 67. 10.5336/cardiosci.2020-75417
MLA DİNDAŞ FERHAT,Turgut Okan,YILMAZ MEHMET BIRHAN Single-Center Retrospective Evaluation of Clinical Features and Life Expectancy in Mid-Range/Reduced Left Ventricular Ejection Fraction Heart Failure Patients Who Died During Hospitalization. Türkiye Klinikleri Cardiovascular Sciences, vol.32, no.2, 2020, ss.59 - 67. 10.5336/cardiosci.2020-75417
AMA DİNDAŞ F,Turgut O,YILMAZ M Single-Center Retrospective Evaluation of Clinical Features and Life Expectancy in Mid-Range/Reduced Left Ventricular Ejection Fraction Heart Failure Patients Who Died During Hospitalization. Türkiye Klinikleri Cardiovascular Sciences. 2020; 32(2): 59 - 67. 10.5336/cardiosci.2020-75417
Vancouver DİNDAŞ F,Turgut O,YILMAZ M Single-Center Retrospective Evaluation of Clinical Features and Life Expectancy in Mid-Range/Reduced Left Ventricular Ejection Fraction Heart Failure Patients Who Died During Hospitalization. Türkiye Klinikleri Cardiovascular Sciences. 2020; 32(2): 59 - 67. 10.5336/cardiosci.2020-75417
IEEE DİNDAŞ F,Turgut O,YILMAZ M "Single-Center Retrospective Evaluation of Clinical Features and Life Expectancy in Mid-Range/Reduced Left Ventricular Ejection Fraction Heart Failure Patients Who Died During Hospitalization." Türkiye Klinikleri Cardiovascular Sciences, 32, ss.59 - 67, 2020. 10.5336/cardiosci.2020-75417
ISNAD DİNDAŞ, FERHAT vd. "Single-Center Retrospective Evaluation of Clinical Features and Life Expectancy in Mid-Range/Reduced Left Ventricular Ejection Fraction Heart Failure Patients Who Died During Hospitalization". Türkiye Klinikleri Cardiovascular Sciences 32/2 (2020), 59-67. https://doi.org/10.5336/cardiosci.2020-75417